Medical centers are offering patients the option of taking anti-nausea medication to help manage nausea and vomiting, according to a new research paper published online in Neurology.
The medication, Adl, is being marketed as an anti-vomiting medication because it has been shown to be effective against the common and deadly side effects of common medications such as anti-anxiety medication, anti-depressants, and anti-convulsants.
Researchers found that Adl is effective against nausea and other nausea and related side effects in people with chronic, refractory, or relapsing-remitting epilepsy and people with moderate to severe refractories, who have no other medication that is effective.
They used data from the National Institutes of Health National Survey on Drug Use and Health and from other research studies to determine the effectiveness of Adl in treating nausea and nausea-related side effects.
The study is the first to show that Adlon is effective in treating side effects related to nausea and the side effects that stem from it, according the researchers, who also found that it can also be effective in reducing the side effect burden associated with anti-Nausea medications.
Adlon has been approved by the Food and Drug Administration for the treatment of nausea and similar side effects, and is available over the counter in prescription form.
The drug is an amphetamine derivative that blocks the action of norepinephrine and dopamine.
The new study found that the medication, which is a drug of abuse, was effective in preventing nausea and side effects associated with the medication.
The researchers note that the drug has been marketed as anti nausea, anti convulsants, anti anxiety, anti depression, anti nausea drugs, and has also been marketed in clinical trials.
The medications can also help patients with chronic nausea and seizures.
“The drug Adl has proven to be an effective treatment for nausea and associated side effects,” said lead author Kristin Gorman, MD, PhD, of Montefiore Medical Center in New York City.
“The new results suggest that Adlan may be effective as a treatment for the common, recurrent, and refractively refractor-responsive nausea and/or vomiting.
This is exciting news for people with these symptoms, who will be more likely to seek Adlon treatment as their symptoms improve.”
The drug is currently being tested in the trial of patients with moderate-to-severe refractores.
The trial will continue through November, with results expected in mid-2018.